Drug Eruptions Workup

Updated: Jun 29, 2018
  • Author: Jonathan E Blume, MD; Chief Editor: Dirk M Elston, MD  more...
  • Print
Workup

Laboratory Studies

History and physical examination are often sufficient for diagnosing mild asymptomatic eruptions. Severe or persistent eruptions may require further diagnostic testing.

Biopsy can be helpful in confirming the diagnosis of a drug eruption (eg, by showing eosinophils in morbilliform eruptions or numerous neutrophils without vasculitis in persons with Sweet syndrome).

CBC count with differential may show leukopenia, thrombocytopenia, and eosinophilia in patients with serious drug eruptions.

Serum chemistry studies may be useful. Liver involvement leading to death can occur in persons with hypersensitivity syndromes. Special attention should be paid to the electrolyte balance and renal and/or hepatic function indices in patients with severe reactions such as SJS, TEN, or vasculitis.

Antibody and/or immunoserology tests may be ordered. Antihistone antibodies are noted in persons with drug-induced SLE, whereas anti-Ro/SS-A antibodies are most common in persons with drug-induced SCLE.

Direct cultures may be needed to investigate a primary infectious etiology or secondary infection.

Urinalysis, stool guaiac tests, and chest radiography are important for patients with vasculitis.

Next:

Imaging Studies

Chest radiography, along with urinalysis and stool guaiac tests, is important for patients with vasculitis.

Previous
Next:

Other Tests

Rechallenge tests by means of skin prick or patch testing to confirm the causative agent is of limited value. Skin tests may be hazardous to patients who have had severe reactions. With the possible exception of acute generalized exanthematous pustulosis (AGEP), patch tests have a low sensitivity and specificity and are not useful. [45]

Previous
Next:

Histologic Findings

In some cases, biopsy may be helpful in establishing a diagnosis of a drug reaction.

Histopathology of an exanthematous drug eruption may show both superficial and deep perivascular inflammatory cell infiltrates. Eosinophils in the infiltrate suggest such a drug eruption (see the image below).

Superficial perivascular inflammatory infiltrate w Superficial perivascular inflammatory infiltrate with numerous eosinophils characteristic of an exanthematous drug eruption.

In patients with Sweet syndrome, biopsy reveals edema of the superficial dermis and a dense infiltrate of neutrophils. Leukocytoclasia may be present, but vasculitis is absent.

Histopathology of TEN shows subepidermal split, full-thickness epidermal necrosis and a sparse perivascular lymphocytic infiltrate (see the image below).

Confluent necrosis of the epidermis in toxic epide Confluent necrosis of the epidermis in toxic epidermal necrolysis.
Previous